Physician profile
Aakash Goyal
NPI 1447468988
$1,565.51
in general payments reported to CMS, 2019-2025
12 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $72.82 · 2021: $182 · 2022: $139 · 2023: $304 · 2024: $233 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.29 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $393.97 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $287.34 | 2022-2024 | Stelara, Tremfya |
| Abbvie INC. | $271.28 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $261.10 | 2022-2025 | Dupixent |
| Genzyme Corporation | $161.89 | 2024-2025 | |
| Alcresta Therapeutics, INC. | $50.91 | 2023-2024 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $36.16 | 2023-2025 | Eohilia, Gattex |
| Pharming Healthcare, INC. | $34.20 | 2023 | Ruconest |
| Amgen INC. | $24.84 | 2023 | Amjevita, Avsola |
| Mauna Kea Technologies, INC. | $23.85 | 2025 | |
| Boston Scientific Corporation | $19.97 | 2025 | Accolade Sr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakash Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.